Mannin Research Inc.
  • Home
  • Team
  • Lead Technology
  • News
  • Contact Us

Europe

  • Mannin announces $10.1M grant, part of $15.65M investment to develop new therapeutics for glaucoma

    Senior Leadership team to expand with Isabel Antholz joining as Managing Director Toronto, Canada and Leipzig, Germany, November 27,2019 Mannin Research Inc. (Mannin), is pleased to announce that its wholly owned subsidiary, Mannin GmbH, has received a substantial €6.9M ($10.1M CAD) grant, from the Free State of Saxony, in Germany. This grant is a contribution to a multi-year €10.7M ($15.65M CAD) investment by Mannin into its German research and...

Pages

  • Contact Us
  • Home
  • Lead Technology
  • News
  • Team

Recent Posts

  • Mannin and Cyclica Enter JV to Rapidly Develop COVID-19 Drugs
  • Mannin Research Inc. Presents Data Showing Potential Treatment to Protect Kidney in Acute Kidney Injury Using Mannin Tie2 Activator

Categories

  • Archives
  • News
Mannin Research Inc.
Mannin Research Inc. is a biotechnology company leading the development of a new class of vascular therapeutics.
  • 629 Eastern Avenue, Suite C300 Toronto, Ontario M4M 1E4
  • (416) 775 9767
  • @info@mannin.ca

Recent Tweets

RECENT POSTS

  • Mannin and Cyclica Enter JV to Rapidly Develop COVID-19 Drugs
  • Mannin Research Inc. Presents Data Showing Potential Treatment to Protect Kidney in Acute Kidney Injury Using Mannin Tie2 Activator
Mannin Research Inc., Copyright 2016, All Rights Reserved
  • Home
  • Team
  • Lead Technology
  • News
  • Contact Us